Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

AIMS: We investigated the incremental advantage in terms of N-terminal pro-B-type natriuretic peptide (NT-proBNP) reduction in patients affected by heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (S/V) and mineralocorticoid receptor antagonists (MRA) versus pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Benini, Annachiara, Bingel, Anne, Neumann, Konrad, Edelmann, Frank, Schönrath, Felix, Pieske, Burkert, Messroghli, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Heart Failure and Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772686/
https://www.ncbi.nlm.nih.gov/pubmed/36543361
http://dx.doi.org/10.1136/openhrt-2022-002069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772686/
https://www.ncbi.nlm.nih.gov/pubmed/36543361
http://dx.doi.org/10.1136/openhrt-2022-002069

Ejemplares similares